Acquired hemophilia treatment market projected to reach $15.91 billion by 2030

The acquired hemophilia treatment market is expanding as awareness rises, clinical research accelerates and new therapies emerge. The Business Research Company projects the market will grow from $12.83 billion in 2025 to $15.91 billion by 2030, with North America leading and Asia-Pacific set to grow fastest.

Why it matters: - Acquired hemophilia is a rare bleeding disorder, so market growth points to broader diagnosis, treatment access and research activity. - The market’s expansion reflects rising demand for specialized therapies and better management of bleeding episodes. - Growth in this niche treatment area can shape how quickly patients get access to new therapies, including gene therapy and personalized medicine.

What happened: - The Business Research Company said the acquired hemophilia treatment market reached $12.83 billion in 2025. - The market is forecast to rise to $13.39 billion in 2026. - The company projects the market will reach $15.91 billion by 2030. - The projected growth rate is 4.4% CAGR across the forecast period. - The outlook was published Oct. 28, 2026, from London. - The report includes a free sample and a full market report link: More information and the full report.

The details: - Market growth has been driven by limited availability of specialized hemophilia therapies. - The number of acquired hemophilia cases is increasing. - Care remains heavily centered in hospitals. - Awareness of bleeding disorders has increased. - Demand is shifting toward on-demand treatment models. - Future growth is expected to be supported by gene therapy advances. - Broader use of prophylactic treatments is also expected to support expansion. - The rise of personalized hematology medicine is another growth factor. - More investment in hemophilia research is expected to add momentum. - Improved access to sophisticated therapies in emerging markets is part of the longer-term outlook. - The market analysis says North America was the dominant region in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The regional scope also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Acquired hemophilia treatment focuses on controlling bleeding episodes and eliminating inhibitors that interfere with clotting factors. - The underlying condition is described as a rare bleeding disorder caused by genetic mutations or alterations that affect clotting factor protein production.

Between the lines: - The report points to a market being pushed by both clinical need and research activity. - A December 2024 Association of the British Pharmaceutical Industry report showed UK pharmaceutical industry trials increased from 411 in 2022 to 426 in 2023. - More clinical trials can speed validation of new therapies and diagnostics, which can improve treatment standards over time. - The report’s emphasis on prophylaxis, personalization and gene therapy suggests the market is moving beyond emergency bleeding control toward more preventive care.

What's next: - The market will likely track progress in gene therapy, clinical trials and access to advanced care. - Emerging markets may become more important as therapy availability broadens. - Further awareness efforts and early diagnosis programs could strengthen adoption of newer treatment approaches. - The Business Research Company said its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards and hotspot infographics.

The bottom line: - The acquired hemophilia treatment market is small but expanding steadily, with research, awareness and advanced therapies expected to keep demand rising through 2030.